United Kingdom Targeted Liposomes Drug Delivery Market Insight
The United Kingdom Targeted Liposomes Drug Delivery Market is growing at an 15.9% CAGR, driven by rising cancer cases, targeted therapies demand, and nanotechnology advancements improving efficacy and safety
United Kingdom Targeted Liposomes Drug Delivery Market Insights Forecasts to 2035
- The United Kingdom Targeted Liposomes Drug Delivery Market Size Was Estimated at USD 5.0 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 15.9% from 2025 to 2035
- The United Kingdom Targeted Liposomes Drug Delivery Market Size is Expected to Reach USD 21.86 Billion by 2035
Notable Insights for United Kingdom Targeted Liposomes Drug Delivery Market
- By product type, PEGylated liposomes dominated, accounting for approximately 55–60% share in 2024, driven by improved circulation time and reduced immune clearance.
- By application, oncology held approximately 65–70% share, due to increasing use of liposomal formulations in targeted cancer therapies.
- Approximately 20–25% of advanced cancer treatments in the UK incorporate liposomal or nanoparticle-based drug delivery systems, reflecting rising adoption of precision medicine.
- Around 60–70% of healthcare providers prefer targeted liposomal therapies for critical treatments due to enhanced efficacy, reduced systemic toxicity, and improved therapeutic index.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Targeted Liposomes Drug Delivery Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Targeted Liposomes Drug Delivery Market
- Gilead Sciences
- GlaxoSmithKline
- Roche
- Johnson & Johnson
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
- Ipsen
- Others
Recent Developments:
- In March 2026, University of Nottingham scientists developed a modular RNA delivery platform forming nanoscale particles, accelerating vaccines and cancer therapies development.
- In March 2025, targeted liposome research advanced using glutathione-coated vesicles to cross the blood–brain barrier, improving glioblastoma treatment outcomes.
Market Segmentation:
United Kingdom Targeted Liposomes Drug Delivery Market, By Product Type
- PEGylated Liposomes
- Conventional Liposomes
- Ligand-Targeted Liposomes
- Stimuli-Responsive Liposomes
- Others
United Kingdom Targeted Liposomes Drug Delivery Market, By Application
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
United Kingdom Targeted Liposomes Drug Delivery Market, By End User
- Hospitals & Clinics
- Research Institutes
- Specialty Centers
United Kingdom Targeted Liposomes Drug Delivery Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Targeted Liposomes Drug Delivery Market is expected to expand significantly due to growing demand for precision medicine and targeted therapeutics. Experts highlight that oncology will remain the dominant application, supported by increasing cancer incidence and innovation in nanocarrier systems. Advances in ligand-targeting, PEGylation, and stimuli-responsive liposomes are anticipated to broaden therapeutic applications. Additionally, ongoing research in personalized medicine and biologics integration will further enhance treatment efficacy and accelerate market growth through 2035.